Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (CA3011372) COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS

Office : Canada
Application Number: 3011372 Application Date:
Publication Number: 3011372 Publication Date: 17.08.2017
Publication Kind : A1
Prior PCT appl.: Application Number:PCTUS2017017435 ; Publication Number: Click to see the data
IPC:
A61K 45/06
C07K 16/30
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
CPC:
A61K 31/4535
A61K 31/473
A61K 31/4985
A61K 39/3955
A61K 45/06
A61K 47/6803
A61K 47/6851
A61K 47/6889
A61K 51/1057
C07K 16/2887
C07K 16/30
C07K 16/3007
C07K 16/3015
C07K 16/3023
C07K 16/303
C07K 16/3038
C07K 16/3046
C07K 16/3053
C07K 16/3061
C07K 16/3069
C07K 16/3092
C07K 2317/24
C07K 2317/732
C07K 2317/77
C07K 2317/90
C07K 2317/92
A61K 31/4745
A61K 41/0038
C07K 2317/565
Applicants: IMMUNOMEDICS, INC.
Inventors:
Priority Data: 62/293,530 10.02.2016 US
62/329,788 29.04.2016 US
62/336,985 16.05.2016 US
Title: (EN) COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS
(FR) LA COMBINAISON INHIBITEURS ABCG2-SACITUZUMAB GOVITECAN (IMMU-132) SURMONTE LA RESISTANCE A SN-38 DANS LES CANCERS EXPRIMANT TROP-2
Abstract: front page image
(EN) The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.


Also published as:
CN108601841IN201817027046EP3413914WO/2017/139623